natgillin/translations-raw huggingface dataset:
In a single oral dose (10 mg) Positron Emission tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy.
V študiji pozitronske emisijske tomografije (PET) s posameznim peroralnim odmerkom (10 mg) pri zdravih prostovoljcih je olanzapin povzro il višjo zasedenost 5- HT2A kot dopaminskih D2 receptorjev.
In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
Pri dveh od dveh s placebom kontroliranih in dveh od treh primerjalno kontroliranih preskušanjih pri ve kot 2900 bolnikih s shizofrenijo, ki so kazali tako pozitivne kot negativne simptome, je bil olanzapin povezan s statisti no zna ilnim ve jim izboljšanjem negativnih in tudi pozitivnih simptomov.
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
V dvojno slepi primerjalni študiji shizofrenije, shizoafektivnih in sorodnih motenj, v kateri je sodelovalo ve držav in je vklju evala 1481 bolnikov z razli nimi stopnjami pridruženih depresivnih simptomov (izhodiš na srednja vrednost 16, 6 na Montgomery- Asbergovi lestvici ocenjevanja depresije), je prospektivna sekundarna analiza spremembe od izhodiš ne do kon ne ocene razpoloženja pokazala statisti no zna ilno izboljšanje (p = 0, 001) v korist olanzapina (– 6, 0) v primerjavi s haloperidolom (– 3, 1).
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
12 Pri bolnikih z mani no ali mešano epizodo bipolarne motnje je olanzapin pokazal ve jo u inkovitost kot placebo in seminatrijev valproat (divalproeks) pri znižanju mani nih simptomov v treh tednih.
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapin je prav tako pokazal rezultate u inkovitosti, primerljive s haloperidolom, glede na delež bolnikov v simptomatski remisiji manije in depresije po 6 in 12 tednih.
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
V študiji so asnega zdravljenja bolnikov z litijem ali valproatom vsaj 2 tedna je dodatek 10 mg olanzapina (so asno zdravljenje z litijem ali valproatom) povzro il ve je zmanjšanje simptomov manije po 6 tednih kot pri monoterapiji z litijem ali valproatom.
In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.
V 12- mese ni študiji prepre evanja ponovitve bolezni pri bolnikih z mani no epizodo, ki so z zdravljenjem z olanzapinom dosegli remisijo in so jim nato naklju no dodelili prejemanje olanzapina ali placeba, je bil olanzapin statisti no zna ilno boljši kot placebo ob primarni kon ni to ki ponovitve bipolarne motnje.
Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.
Olanzapin je pokazal tudi statisti no zna ilno prednost pred placebom glede prepre evanja ponovnega pojava ali manije ali depresije.
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p = 0.055).
V drugi 12- mese ni študiji prepre evanja ponovitve bolezni pri bolnikih z mani no epizodo, ki so z zdravljenjem s kombinacijo olanzapina in litija dosegli remisijo in so jim nato naklju no dodelili prejemanje samo olanzapina ali samo litija, ni bil olanzapin statisti no zna ilno ni slabši kot litij ob primarni kon ni to ki ponovitve bipolarne motnje (olanzapin 30, 0%, litij 38, 3%; p = 0, 055).
12 In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
V 18- mese ni študiji so asnega zdravljenja pri bolnikih z mani no ali mešano epizodo, stabiliziranih z olanzapinom skupaj s stabilizatorjem razpoloženja (litij ali valproat), dolgotrajno so asno zdravljenje z olanzapinom skupaj z litijem ali valproatom ni bilo statisti no zna ilno bolj ugodno kot zdravljenje samo z litijem ali samo valproatom pri odlogu ponovnega pojava bipolarne motnje, dolo ene po sindromnih (diagnosti nih) merilih.
Paediatric population The experience in adolescents (ages 13 to 17 years) is limited to short term efficacy data in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents.
Pediatri na populacija Izkušnje pri mladostnikih (starih 13 do 17 let) so omejene na kratkoro ne podatke o u inkovitosti pri shizofreniji (6 tednov) in maniji povezani z bipolarno I motnjo (3 tedni), ki vklju ujejo manj kot 200 mladostnikov.
Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/ day.
Olanzapin so uporabljali kot prilagodljiv odmerek, ki so ga za eli z 2, 5 mg in zviševali do 20 mg/ dan.
During treatment with olanzapine, adolescents gained significantly more weight compared with adults.
Med zdravljenjem z olanzapinom so mladostniki pove ali signifikantno ve telesne mase v primerjavi z odraslimi.
The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults.
Obseg sprememb v celokupnem holesterolu na teš e, LDL holesterolu, trigliceridih in prolaktinu (glejte poglavji 4. 4 in 4. 8) je bil ve ji pri mladostnikih kot pri odraslih.
There are no data on maintenance of effect and limited data on long term safety (see sections 4.4 and 4.8).
Podatkov o vzdrževalnem u inku ni in podatki o dolgoro ni varnosti so nezadostni (glejte poglavji 4. 4 in 4. 8).
Absolute oral bioavailability relative to intravenous administration has not been determined
Absolutna peroralna biološka uporabnost glede na intravensko dajanje ni bila dolo ena.
The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier.
V krvi je poglavitni metabolit 10 - N- glukuronid, ki ne prehaja skozi krvno- možgansko pregrado.
The predominant pharmacologic activity is from the parent olanzapine.
Prevladujo a farmakološka aktivnost izvira iz samega olanzapina.
After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.
Po peroralnem dajanju se je srednji kon ni razpolovni as izlo anja olanzapina pri zdravih osebah razlikoval glede na starost in spol.
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/ hr).
Pri zdravih starejših osebah (65 let in ve) v primerjavi z nestarejšimi je bil srednji razpolovni as izlo anja podaljšan (51, 8 v primerjavi s 33, 8 ure) in o istek zmanjšan (17, 5 v primerjavi z 18, 2 l/ h).
The pharmacokinetic variability observed in the elderly is within the range for the non-elderly.
Pri
In 44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/ day was not associated with any distinguishing profile of adverse events.
13 44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/ dan ni bilo povezano s kakim razlo evalnim profilom neželenih u inkov.
In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/ hr).
Pri ženskah v primerjavi z moškimi je bil srednji razpolovni as izlo anja nekoliko podaljšan (36, 7 v primerjavi z 32, 3 ure) in o istek zmanjšan (18, 9 v primerjavi s 27, 3 l/ h).
In renally impaired patients (creatinine clearance < 10 ml/ min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/ hr).
Pri bolnikih z okvarjenim delovanjem ledvic (o istek kreatinina < 10 ml/ min) v primerjavi z zdravimi osebami ni bilo zna ilne razlike v srednjem razpolovnem asu izlo anja (37, 7 v primerjavi z 32, 4 ure) ali o istku (21, 2 v primerjavi s 25, 0 l/ h).
A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites.
Študija bilance snovi je pokazala, da se približno 57% radioaktivno ozna enega olanzapina pojavi v urinu, predvsem v obliki metabolitov.
In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
Pri kadilcih z blagimi motnjami v delovanju jeter je bil srednji razpolovni as izlo anja (39, 3 ure) podaljšan in o istek (18, 0 l/ h) zmanjšan tako kot pri zdravih nekadilcih (48, 8 ur oziroma 14, 1 l/ h).
In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/ hr).
V primerjavi nekadilcev s kadilci (moškimi in ženskami) je bil srednji razpolovni as izlo anja podaljšan (38, 6 v primerjavi s 30, 4 ure) in o istek zmanjšan (18, 6 l/ h v primerjavi s 27, 7 l/ h).
However, the magnitude of the impact of age, gender, or
Plazemski o istek olanzapina je manjši pri starejših v primerjavi z mlajšimi, pri ženskah v primerjavi z moškimi in pri nekadilcih v primerjavi s kadilci.
13 smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.
Vendar pa je vpliv starosti, spola ali kajenja na o istek in razpolovni as olanzapina majhen v primerjavi s povpre no variabilnostjo med posamezniki.
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.
V študiji pri belcih, Japoncih in Kitajcih ni bilo razlik v farmakokineti nih parametrih med temi tremi populacijami.
Paediatric population Adolescents (ages 13 to 17 years):
Pediatri na populacija Mladostniki (stari 13 do17 let):
In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents.
V klini nih študijah je bila povpre a izpostavitev približno 27% višja pri mladostnikih.
Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers.
Demografske razlike med mladostniki in odraslimi vklju ujejo nižjo povpre no telesno maso ter manj mladostnikov je bilo kadilcev.
Such factors possibly contribute to the higher average exposure observed in adolescents.
Možno je, da taki dejavniki vplivajo na višjo povpre no izpostavitev, ki so jo opazili pri mladostnikih.
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
Akutna toksi nost (toksi nost po enkratnem odmerku) Znaki toksi nosti po peroralnem dajanju pri glodavcih so bili zna ilni za mo ne antipsihotike: hipoaktivnost, koma, tresenje, kloni ni kr i, slinjenje in zmanjšano pridobivanje telesne mase.
Clinical signs included sedation, ataxia, tremors, increased heart rate, labored respiration, miosis, and anorexia.
Klini ni znaki so vklju evali sedacijo, ataksijo, tresenje, zvišano sr no frekvenco, težko dihanje, miozo in izgubo apetita.
In monkeys, single oral doses up to 100 mg/ kg resulted in prostration and, at higher doses, semi-consciousness.
Pri opicah so enkratni peroralni odmerki do 100 mg/ kg povzro ili oslabelost in pri višjih odmerkih moteno zavest.
Repeated-dose toxicity In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders.
Toksi nost po ve kratnem odmerjanju V študijah, ki so pri miših trajale do 3 mesece, pri podganah in psih pa do 1 leta, so bili prevladujo i u inki depresija osrednjega živ evja, antiholinergi ni u inki in periferne hematološke motnje.
Tolerance developed to the CNS depression.
Za depresijo osrednjega živ evja se je razvila toleranca.
Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland.
Reverzibilni u inki v skladu s zvišano koncentracijo prolaktina so pri podganah vklju evali znižano maso jaj nikov in maternice ter morfološke spremembe epitelija nožnice in mle ne žleze.
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
14 Hematološka toksi nost Pri vsaki vrsti so odkrili u inke na hematološke parametre, vklju no z z odmerkom povezanimi znižanji koncentracij levkocitov v obtoku pri miših in nespecifi nim znižanjem koncentracije levkocitov v obtoku pri podganah; vendar pa niso našli dokazov citotoksi nosti za kostni mozeg.
Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/ kg/ day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Pri nekaj psih, ki so prejemali 8 ali 10 mg/ kg/ dan (celotno izpostavljanje olanzapinu [površina pod krivuljo] je 12 - do 15- krat ve je kot pri loveku, ki dobi 12- miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.
Pri psih z izraženo citopenijo ni bilo neželenih u inkov na progenitorne in proliferirajo e celice v kostnem mozgu.
Reproductive toxicity Olanzapine had no teratogenic effects.
Vpliv na sposobnost razmnoževanja Olanzapin ni imel teratogenih u inkov.
Estrous cycles were affected at doses of 1.1 mg/ kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/ kg (9 times the maximum human dose).
Odmerki 1, 1 mg/ kg (3- kratni maksimalni odmerek za loveka) so vplivali na estrus cikluse, odmerki 3 mg/ kg (9- kratni maksimalni odmerek za loveka) pa so pri podganah vplivali na parametre reprodukcije.
Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Mutagenost Olanzapin ni bil mutagen ali klastogen v širokem razponu standardnih testov, ki je vklju eval teste mutiranja bakterij ter in vitro in in vivo teste na sesalcih.
Carcinogenicity Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
Kancerogenost Na podlagi izsledkov študij peroralnega olanzapina na miših in podganah je bilo zaklju eno, da olanzapin ni kancerogen.
Gelatin Mannitol (E421) Aspartame (E951) Sodium methyl parahydroxybenzoate (E219) Sodium propyl parahydroxybenzoate (E217)
želatina manitol (E421) aspartam (E951) natrijev metilparahidroksibenzoat (E219) natrijev propilparahidroksibenzoat (E217)
Store in the original package in order to protect from light and moisture.
Shranjujte v originalni ovojnini za zagotovitev zaš ite pred svetlobo in vlago.
Aluminium blister strips in cartons of 28, 35, 56 or 70 orodispersible tablets per carton.
Aluminijasti pretisni omoti v škatlah po 28, 35, 56 ali 70 orodisperzibilnih tablet.
3 February 2000 Date of latest renewal:
3. februar 2000 Datum zadnjega podaljšanja dovoljenja za promet:
ZYPREXA VELOTAB 10 mg orodispersible tablets
ZYPREXA VELOTAB 10 mg orodisperzibilne tablete
For a full list of excipients, see section 6.1.
Vsaka orodisperzibilna tableta vsebuje 0, 80 mg aspartama 0, 15 mg natrijevega metilparahidroksibenzoata 0, 05 mg natrijevega propilparahidroksibenzoata Za celoten seznam pomožnih snovi glejte poglavje 6. 1.
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/ day.
17 Med zdravljenjem shizofrenije, mani ne epizode in prepre evanjem ponovnega pojava bipolarne motnje se lahko dnevni odmerek na podlagi individualnega klini nega stanja kasneje prilagodi v razponu 5 do 20 mg na dan.
Elderly A lower starting dose (5 mg/ day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).
Starejši Nižji za etni odmerek (5 mg na dan) ni rutinsko priporo en, vendar ga je treba upoštevati pri bolnikih, starih 65 let in ve, kadar to upravi ujejo klini ni dejavniki (glejte tudi poglavje 4. 4).
4.4 Special warnings and precautions for use
18 4. 4 Posebna opozorila in previdnostni ukrepi
17 Dementia-related psychosis and/ or behavioural disturbances Olanzapine is not approved for the treatment of dementia-related psychosis and/ or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident.
Psihoza povezana z demenco in/ ali vedenjske motnje Olanzapin ni odobren za zdravljenje bolnikov s psihozo, povezano z demenco in/ ali vedenjskimi motnjami ter ni priporo ljiv za uporabo pri teh skupinah bolnikov zaradi pove ane umrljivosti in tveganja za cerebrovaskularne dogodke.
Appropriate clinical monitoring is advisable particularly in diabetic patients and in patients with risk factors for the development of diabetes mellitus for which regular glucose control is recommended.
19 sladkorne bolezni, za katero je priporo en reden nadzor glukoze, je priporo eno ustrezno klini no spremljanje.
18 Anticholinergic activity While olanzapine demonstrated anticholinergic activity in vitro, experience during the clinical trials revealed a low incidence of related events.
Antiholinergi no delovanje Medtem ko je olanzapin pokazal antiholinergi no delovanje v pogojih in vitro, so izkušnje klini nih preskušanj razkrile majhno incidenco s tem povezanih dogodkov.
General CNS activity Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol.
20 Splošno delovanje na osrednje živ evje Glede na primarne u inke olanzapina na osrednje živ evje je potrebna previdnost, kadar se ga jemlje v kombinaciji z drugimi osrednje delujo imi zdravili in alkoholom.
19 Tardive Dyskinesia In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia.
Tardivne diskinezije V primerjalnih študijah, ki so trajale eno leto ali manj, so olanzapin povezovali s statisti no zna ilno manjšo incidenco diskinezij, ki se pojavijo ob zdravljenju.
Sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate Olanzapine orodispersible tablet contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate.
Natrijev metilparahidroksibenzoat in natrijev propil parahidroksibenzoat Orodisperzibilna tableta olanzapina vsebuje natrijev metilparahidroksibenzoat in natrijev propilparahidroksibenzoat.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (See section 4.2).
Klini ne posledice so verjetno omejene, vendar je priporo eno spremljanje klini nega stanja in zvišanje odmerka olanzapina, e je potrebno (glejte poglavje 4. 2).
Inhibition of CYP1A2 Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
21 Zaviranje CYP1A2 Fluvoksamin, specifi ni zaviralec CYP1A2, je pokazal pomembno zaviranje presnove olanzapina.
20 Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.
Za fluoksetin (zaviralec CYP2D6), posamezne odmerke antacida (aluminij, magnezij) ali cimetidina niso ugotovili, da bi zna ilno vplivali na farmakokinetiko olanzapina.
Mean infant exposure (mg/ kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/ kg) Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Srednjo izpostavitev dojen ka (mg/ kg) v stanju dinami nega ravnovesja so ocenili na 1, 8% materinega odmerka olanzapina (mg/ kg). e jemljejo olanzapin, naj se bolnicam dojenje dojen ka odsvetuje.
4.7 Effects on ability to drive and use machines
22 4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Vascular disorders
23 Sr ne bolezni Žilne bolezni
22 Hepato-biliary disorders
Bolezni jeter, žol nika in žol evodov Bolezni kože in podkožja
Weight gain 7% of baseline body weight was very common and 15% of baseline body weight was common.
Zve anje telesne mase za 7% od osnovne telesne mase je bilo zelo pogosti ter pogosto za 15%.
3 Observed for fasting normal levels at baseline (< 5.17 mmol/ l) which increased to high (6.2 mmol/ l).
24 3 Opazovano pri osnovnih normalnih ravneh na teš e (< 5, 17 mmol/ l), ki so se povišale na visoke (6, 2 mmol/ l).
23 7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.
7 Pri nenadni prekinitvi zdravljenja z olanzapinom so poro ali o akutnih simptomih kot so znojenje, nespe nost, tresenje, tesnoba, slabost in bruhanje.
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short- term clinical trials in adolescent patients.
25 Naslednja tabela vklju uje neželene u inke, ki so jih poro ali z višjo pogostnostjo pri mladostnikih (starih 13- 17 let) kot pri odraslih bolnikih ali neželene u inke, ki so jih ugotovili samo v kratkoro nih klini nih preskušanjih pri mladostnikih.
24 Metabolism and nutrition disorders Very common:
Presnovne in prehranske motnje Zelo pogosti:
Management of overdose There is no specific antidote for olanzapine.
26 Ravnanje v primeru prevelikega odmerjanja Za olanzapin ni specifi nega antidota.
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
27 Pri bolnikih z mani no ali mešano epizodo bipolarne motnje je olanzapin pokazal ve jo u inkovitost kot placebo in seminatrijev valproat (divalproeks) pri znižanju mani nih simptomov v treh tednih.